Tuesday, 22 May 2018

Tuberculosis Vaccine Market - Latest Advancements & Market Outlook 2018 to 2026

Tuberculosis (TB) is a highly contagious disease caused by the bacterium known as Mycobacterium tuberculosis and is mostly spread through person to person contact. It causes multisystem infection and eventually might lead to death of the infected person. Two types of TB that are commonly observed include latent TB in which the infected person do not show symptoms and active TB in which the infected person shows clinical symptoms of TB. Clinical symptoms and signs of TB include fever, night sweats, cough, weight loss, hemoptysis (coughing up blood-stained sputum), fatigue, chest pain, and shortness of breath. Depending upon the symptoms, TB may be classified as pulmonary TB, subcutaneous TB or military TB. Depending on the resistance it shows, TB may be multidrug resistant TB or extended drug resistant TB. Diagnosis of tuberculosis can be carried out using skin test, polymerase chain reaction test or interferon-gamma release assays. Initial treatment regime for active TB includes drugs such as ethambutol, pyrazinamide, isoniazid, and rifampicin. Although currently no TB vaccine is approved commercially, children are vaccinated with BCG vaccine as a part of precautionary measure. However, BCG vaccine has limited utility and variable efficacy in both adults and children. Many TB vaccines are under the stage of clinical development, which are expected to reach the market in the near future.

To get detailed table of content (ToC), please click: https://www.coherentmarketinsights.com/insight/request-sample/1602

Tuberculosis Vaccine Market Dynamics

Tuberculosis account for the highest amount of death caused due to infectious disease across the globe. According to the World Health Organization (WHO) factsheet 2018 on TB, 10.4 million people fell ill with TB in 2016 and 1.7 million people with TB died in the same year. More than 95% of TB deaths occur in low- and middle-income economies. Deaths caused due to TB also includes death of 0.4 million people infected with HIV. Such high number of patients across the world confirms the enormity of disease and urgent requirements for vaccines worldwide. Therefore, the launch of tuberculosis vaccine would gain significant revenue and in turn, would propel the market growth. According to a global report on tuberculosis vaccine in 2018, TB costs around US$ 21 billion annually to global economy. Another important impetus to tuberculosis vaccine market would be current complex drug regime and resistance TB has created to this drug regime. TB patient has to take more than 2-3 drugs for prolonged time period of 6 months in order to suppress the infection. Often this results in the poor patient compliance and eventually leads to drug resistance incidence which further deteriorate the TB. According to WHO, there were nearly 600,000 new cases with resistance to rifampicin antibiotic, which was the most effective first-line drug in 2017, of which around 490,000 had MDR-TB globally. If effective steps won’t be taken by 2050, MDR-TB alone could cost the world US$ 16.7 trillion as per global report on tuberculosis vaccine 2018. Drug toxicity due to high daily dose and prolonged treatment is another concern with current TB drugs. Although the cost of TB drug is not much of concern in developing economies due to government support and free medication, it is a matter of concern in developed countries such as the U.S. and Europe. Increased recognition of TB’s fatality by intergovernmental organization and national government would prosper funding for TB vaccine research. Increased research and development activities for development of vaccine against TB by companies and intergovernmental organizations is expected to boost growth of tuberculosis vaccine market. For instance, Aeras is an NGO, which supports TB vaccine development and has helped develop 9 TB vaccine candidates and conducted over 35 Phase 1-2b clinical trials.

Tuberculosis Vaccine Market - Regional Insights

TB is most prevalent in middle and low income economies in Asia Pacific and Africa and therefore, these regions would represent greatest opportunity for the potential TB vaccine. According to the World Health Organization factsheet 2018 on TB, countries such as India, China, Indonesia, Philippines, Pakistan, Nigeria, and South Africa account for around 64% of the total TB deaths. Another risk factor for these regions is the high number of HIV positive population living in this region. Around 40% of deaths among HIV-positive people were due to TB in 2016 as per WHO. Tuberculosis vaccine could prove most beneficial for these regions and in turn, would drive growth of tuberculosis vaccine market. Government initiatives and international support to curb TB incidence would speed up the vaccine development and also would support access for such vaccines. India, which accounts for half a million global TB deaths has launched National Strategic Plan (NSP) for TB Elimination 2017-2025 to combat TB. India also formed India TB Research Consortium to boost TB vaccine and medication research. Developed regions such as North America accounts for significant number of TB patients. According to the Centre for Disease Control, a total of 9,093 TB cases were reported in the U.S. in 2017. MDR-TB and XDR-TB accounted for approximately US$ 160,000 and US$ 513,000 respectively for treatment of each patient. Effective vaccine against TB would gain significant traction in countries such as the U.S.

Request a sample to stay abreast on the key trends impacting this market: https://www.coherentmarketinsights.com/insight/request-sample/1602

Tuberculosis Vaccine Market - Competitive Landscape

Many companies and research institutes are taking efforts to develop tuberculosis vaccine to combat TB. There are fourteen TB vaccines under clinical trials, out of which one investigational candidate named Vaccae from China is in phase three whereas three are in late phase 2. Most of the researches are carried out in academic and research places, which eventually would be transferred to commercial companies for effective distribution and access. Companies are also improving current BCG vaccines, in order to target TB by bringing recombinant vaccine product.
Some of the key players in the tuberculosis vaccine market include GlaxoSmithKline, Sanofi Pasture, Longcom Enterprise Ltd, Biofabri, Valneva plc, and Archivel Farma S.L.

Tuberculosis Vaccine Market Taxonomy:

On the basis of type of vaccine, the global tuberculosis vaccine market is segmented into:
  • Viral Vector Vaccine
  • Recombinant Protein Vaccine
  • Recombinant BCG Vaccine
  • Attenuated Vaccine
  • Others
About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Monday, 21 May 2018

Closed MRI Systems Market - Latest Advancements & Market Outlook 2018 to 2026

Magnetic resonance imaging (MRI) is a non-invasive medical test that uses powerful magnetic field, radio waves, and a computer to produce detailed virtual image of internal organs of the body. Closed MRI systems have a tube-like tunnel with magnetic field of around 1.5 to 3.0 tesla or above to generate detailed image of the organs. Closed MRI system is used in screening and diagnosis of brain, cardiac, spine, breast or abdominal abnormalities. According to European Magnetic Resonance Forum (EMRF) Foundation, the US sale of MRI machine in 2014 / 2015 was approximately 11,500 MRI systems for which one quarter is open system and rest are closed systems. The closed MRI system market is expected to witness growth, owing to its advantages over conventional open MRI and increasing incidence of brain and spinal injuries.

Request a sample to stay abreast on the key trends impacting this market: https://www.coherentmarketinsights.com/insight/request-sample/1610

Closed MRI Systems Market Drivers

Advantages of using closed MRI systems over open MRI systems is expected to be a major factor for growth of the market. Closed MRI systems have field strength of 1.5 Tesla and can reach up to 3.0 Tesla, which can give four to five times clearer imaging results as compared to open MRI system. This advantage of wide range of field strength has led to increasing use of these systems in lesion detection in multiple sclerosis, nerve visibility for brachial plexus, anatomic structures in the wrist or diagnostic accuracy for hepatic metastases.

Increasing awareness about benefits of MRI over X-ray and other imaging techniques using harmful radiation is also expected to propel growth of closed MRI system market in the forecast period. For instance, over the period of January 2016 to January 2017, 3,234,690 patients underwent MRI diagnosis in England. Moreover, increasing number of MRI machine installation is expected to enhance the closed MRI system market growth. For instance, in March 2018, G. Greene Construction Co. installed a Siemens 3T MRI at Boston Children’s Hospital. Furthermore, Cape Breton Regional Hospital installed a new MRI unit, in March 2018. Increasing incidences of spinal and brain injuries is also expected to create a conducive environment for growth of the closed MRI market. For instance, according to 2017 Spinal Cord Injury factsheet of National Spinal Cord Injury Statistical Center (NSCISC), the annual incidence of spinal cord injury in the U.S. is 54 cases per million or about 17,500 new cases each year.

Closed MRI Systems Market Restraint

Owing to its closed structure, several claustrophobic patients suffer from panic attacks during MRI diagnosis. For instance, according to factsheet of 2014 Health Research Funding Organization, up to 13% of the patients suffer from panic attacks due to claustrophobia during MRI diagnosis. This is expected to be a major restraining factor for growth of the market.

Furthermore, high cost of closed MRI system is expected to hinder growth of the closed MRI systems market. Moreover, lack of skilled professionals to handle the systems in emerging countries is a major challenge for growth of the closed MRI system market. In 2016, according to the prediction of Global Health Workforce Labor Market Projections for 2030, global demand for health workers will rise to 80 million workers, double the current (2013) while the supply of health workers is expected to reach 65 million over the same period, resulting in a worldwide net shortage of 15 million health workers. According to World Health Organization (WHO) in 2016, India is lacking with 500,000 doctors. According to the recent study findings by Public Health Foundation of India for Ministry of Health and Family Welfare in 2015, radiography and imaging professionals alone accounts for 88.7% of skill gap out of 97.9% across various health workforce categories, amounting to a huge shortage of medical laboratory technicians.

Closed MRI Systems Market - Regional Analysis

Based on geography, the closed MRI system market has been segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. Europe holds the dominant position in the closed MRI system market over the forecast period, owing to high adoption of closed MRI as compared to open MRI. For instance, according to European Magnetic Resonance Forum (EMRF) Foundation, open systems are mostly sold in the U.S., and the market share of open system is limited in Europe. This is creating a demand for closed MRI systems usage in the diagnosis in Europe.

Closed MRI Systems Market – Competitive Analysis

Key players in the closed MRI systems market are Hitachi, Siemens Healthineers, Canon Medical Systems, GE Healthcare, Philips, Aspect Imaging, Bruker, Aurora Imaging Technology and Esaote S.P.A. Various strategies adopted by key players in closed MRI system market are mergers and acquisitions. For instance, in October 2015, Toshiba acquired medical imaging application developer, Olea Medical. The acquisition is expected to enhance the MRI business of the company by offering Olea’s software for advanced post-processing and image analysis as well as the company’s relationships and agreements with research institutions and customers will aid the MRI business.

Closed MRI Systems Market - Taxonomy

By Strength of Magnetic Field
  • 5 Tesla,
  • 0 Tesla
  • Others
By Application
  • Brain
  • Spine
  • Cardiac
  • Breast
  • Abdominal
By End Users
  • Hospitals
  • Diagnostic Centers
  • Research Institutes
By Region
  • North America
  • Europe
  • Latin America
  • Middle East
  • Asia Pacific
  • Africa
About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Friday, 18 May 2018

Vascular Endothelial Growth Factor Antibodies Market Growth – Key Futuristic Trends and Competitive Landscape 2026

Vascular Endothelial Growth Factor (VEGF) is a signal protein that helps in the formation of new blood vessels through a process known as angiogenesis. Vascular endothelial growth factor is a part of several pathological processes and researches are often carried out for the development of novel therapies using these factors for diseases such as cancer. Normal functions of vascular endothelial growth factor includes embryonic development, formation of new blood vessels, and as a bypass for a blocked vessel. However, overexpression of VEGF often culminates into fatal disease such as cancerous cells. As solid tumors require additional blood supply in order to keep functioning, the overexpression of VEGF serves that purpose through angiogenesis. VEGF family has five members such as VEGF-A, VEGF-B, VEGF-C, VEGF-D, and Placenta Growth Factor (PGF). Out of these growth factors, VEGF-A is responsible for angiogenesis and processes associated with endothelial cells. VEGF-A binds to VEGF receptors on the endothelial cells, which triggers a tyrosine kinase pathway leading to angiogenesis. VEGF-A has been found to be associated with poor prognosis in various cancers, diabetic retinopathy, and age-related macular degeneration. Therapeutic agents are developed to inhibit the transduction pathways of vascular endothelial growth factor (VEGF). Drugs such as monoclonal antibodies against VEGF and tyrosine kinase inhibitors inhibit the angiogenesis process and disease progression.

Request a sample to stay abreast on the key trends impacting this market: https://www.coherentmarketinsights.com/insight/request-sample/1614

Vascular Endothelial Growth Factor (VEGF) Antibodies Market Drivers

Rising prevalence of diseases such as cancer and macular degeneration is expected to boost growth of the market over the forecast period. According to the American Cancer Society, in 2017, cancer was the second most common cause of death in the U.S., which accounts for nearly 1 out of every 4 deaths. Novel therapies such as monoclonal antibodies and angiogenesis inhibitors are highly specialized targeted therapies, which directly targets the cancerous cells. The preference for targeted therapies is rising, owing to the advantages (lesser side effects) offered by targeted therapies over conventional therapies such as chemotherapy. Furthermore, robust pipeline of VEGF antibodies is expected to boost the market growth over the forecast period. For instance, Brolucizumab (Alcon) is in phase 3 clinical trials, Abicipar (Allergan Plc) is in phase 3 trials, and RG7716 (Genentech) is in phase 2 trials, all indicated for age-related macular degeneration. Moreover, Tecentriq manufactured by Roche received the U.S. FDA priority review status to treat people with metastatic non-squamous non-small cell lung cancer in May 2018. Therapies already present in the market have shown improved clinical outcome in cancer as well as age-related macular degeneration (AMD). For instance, Lucentis, as well as Avastin have shown significant improvement in medical outcomes in associated indications such as cancer. These therapies have spurred the interest of manufacturers to further carry out research in this category, which is shown in terms of number of agents present in the pipeline. Blockbuster drugs such as Avastin and Lucentis allow manufacturers to invest in research and development of such therapies, in order to generate the revenues later on while providing the benefits to patients as well. These factors are expected to foster growth of the market over the forecast period.

However, high costs of these medications, biosimilar research, and subsequent launches are expected to hamper the growth of the market. The U.S. Food & Drug Administration has already approved Mvasi (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab) in December 2017. Moreover, European Commission approved biosimilar to Avastin (bevacizumab) in January 2018.

Vascular Endothelial Growth Factor (VEGF) Antibodies Market Insights

On the basis of region, North America and Europe are expected to show significant growth in the vascular endothelial growth factor antibodies market over the forecast period. North America has the presence of leading manufacturers who are indulged in research and development of these therapies. Manufacturers such as Novartis (Europe) and Genentech have these therapies in pipeline and are expected to enter into the market over the forecast period. Asia Pacific region is expected to show modest growth, owing to high costs of these therapies and fairly low availability overall the region. Sophisticated insurance facilities such as Medicaid and Medicare are not present in the developing economies due to which patients cannot afford costly medical treatment in these regions. However, insurance facilities are expected to drive growth of the market in North America.

Key players operating in the vascular endothelial growth factor (VEGF) antibodies market include Genentech, Inc., Novartis, Exelixis, Inc., Eli Lilly and Company, Bayer Pharma AG, Regeneron Pharmaceuticals, Inc., Valeant Pharmaceuticals, Ceres Oncology Pty Ltd, and ThromboGenics, Inc.

Vascular Endothelial Growth Factor (VEGF) Antibodies Market Taxonomy 

The global vascular endothelial growth factor (VEGF) antibodies market is segmented on the basis of drug, route of administration, application, distribution channel, and geography.
By Drug -
  • Avastin
  • Tecentriq
  • Cometriq
  • Eylea
  • Jetrea
  • Cyramza
  • Macugen
  • Lucentis
  • Others
By Route of Administration-
  • Oral
  • Intravenous
  • Intravitreal
  • By Application-
  • Cancer
  • Ophthalmology
  • Others
By Distribution Channel-
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Tuesday, 27 March 2018

Global Vascular Closure Devices Market to Surpass US$ 1440.3 Million Threshold by 2025

The Global Vascular Closure Devices Market by Product Type (Passive Vascular Closure Devices, Active Vascular Closure Devices, and External Hemostatic Devices), By Access (Femoral and Radial), by Hole Size (Small Hole and Large Hole), by End User (Hospitals, Ambulatory Surgical Centers, and Others) and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 848.2 Mn in 2016 and is projected to exhibit a CAGR of 6.1% over the forecast period (2017 – 2025), as highlighted in a new report published by Coherent Market Insights. Multiple approvals and launch of novel innovative devices is expected to support the growth of global vascular closure devices market.

In 2016, Essential Medical, Inc., received CE Mark approval for product MANTA, which is a bore vascular closure device. In 2016, Vasorum Ltd. received U.S. Food and Drug Administration (U.S. FDA) approval for vascular closure device Celt ACD. In 2014, Cardinal Health received U.S. FDA approval for MynxGrip vascular closure device used for closure of femoral veins. The lucrative vascular closure devices market has witnessed multiple product launches in recent years. Thereby, increasing number of products in the market is expected to boost growth of the global vascular closure devices market.

To get holistic SAMPLE of the report including table of contents: https://www.coherentmarketinsights.com/insight/request-sample/1330

Market players are focused on acquiring competitors or particular business segment (i.e. vascular closure device segment) from the competitors in order to increase product portfolio and to strengthen their position in vascular closure devices market. For instance, in January 2017, Terumo Corporation acquired some of vascular closure products owned by Abbott and St. Jude Medical, Inc. for a total amount of US$ 1.12 billion. The acquired product include St Jude Medical’s Angio-Seal and FemoSeal vascular closure product lines and Abbott’s Vado Steerable Sheath. An estimate total revenue generated by these products was US$ 268 Mn in 2016. Furthermore, Abbott Laboratories acquired St. Jude Medical, Inc. in January 2017 in order to strengthen its position in cardiovascular devices including vascular closure devices market. In 2014, Cardinal Health Inc. acquired AccessClosure Inc. for US$ 320 Mn in cash in order to expand vascular closure device product portfolio. In 2017, Teleflex Incorporated have acquired Vascular Solutions, Inc. This strategic acquisition have widen the vascular closure device product portfolio of Teleflex Incorporated.

Browse 34 Market Data Tables and 28 Figures spread through 195 Pages and in-depth TOC on Vascular Closure Device Market, by Product Type (Passive Vascular Closure Devices, Active Vascular Closure Devices, and External Hemostatic Devices), By Access (Femoral, and Radial), By Hole Size (Small Hole, and Large Hole) By End User (Hospital, Ambulatory Surgical Centers, and Others) and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Global Forecast to 2025


Key Takeaways of the Vascular Closure Devices Market:

·         The global vascular closure devices market is expected to exhibit a CAGR of 6.1% over the forecast period (2017 – 2025), owing to frequent approval by regulatory bodies to innovative products in key regions
·         North America is expected to continue dominance during the forecast period (2017 - 2025), owing to launches of novel vascular closure devices in the regions by key players.
·         The market has witnessed multiple product launches in recent years and the trend is expected to continue during the forecast period as leading players are continuously involved in R & D to develop products with efficient technology
·         Mergers/Acquisitions (M&A) and Collaborations has been the major focus of leading companies in this field. Increasing competition in this market may lead to further increase in these activities (M&A and Collaborations).
·         Major players operating in the global vascular closure devices market include Abbott Laboratories, Medtronic Plc, Transluminal Technologies LLC, Cardinal Health, Inc., Cardiva Medical, Inc., Terumo Corporation, Essential Medical, Inc., Vascular Closure Systems, Inc., Vivasure Medical Ltd., Vasorum Ltd., and Morris Innovative Inc

About CMI

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Monday, 26 March 2018

Cholesterol Testing Services Market is expected to Garner US$ 22.6 Bn by 2025

Global Cholesterol Testing Services Market, By Age Group (Geriatric, Adults, and Pediatric), By Service Provider (Hospitals, Diagnostic Laboratories, Ambulatory Care Centers, and Others) and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 11.5 Bn in 2016 and is projected to exhibit a CAGR of 7.8% over the forecast period (2017–2025), as highlighted in a new report published by Coherent Market Insights. Increasing prevalence of high cholesterol level is expected to drive growth of global cholesterol testing services market in the near future.

Browse 27 Market Data Tables and 36 Figures spread through 175 Pages and in-depth TOC on Cholesterol Testing Services Market by Age Group (Geriatric, Adults, and Pediatric), By Service Provider (Hospitals, Diagnostic Laboratories, Ambulatory Care Centers, and Others), and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Global Forecast to 2025


According to a research published by National Heart Foundation of Australia, in 2012, around 5.6 million people aged 18 years and above were reported to have high total cholesterol levels in Australia. High blood cholesterol could lead to risk for developing various heart diseases and stroke, owing to which, people are opting for regular cholesterol checkups. This is expected to increase demand for its testing thus, driving growth of the market in the near future. Furthermore, cholesterol level in plasma increases with age, according to a study published in NCBI in 2013. Hence, rising geriatric population and increasing prevalence of obesity are also expected to be factors aiding in market growth. This is due to high susceptibility of obese and geriatric population to increasing cholesterol levels. For instance, according to a study published by World Health Organization (WHO) in 2014, globally, over 1.9 billion adults aged 18 years and above were overweight, from which over 600 million adults were obese. According to National Institute of Health (NIH) in 2016, around 8.5%, which is 617 million of the world population, is aged 65 and above.

New developments in cholesterol testing, through R&D is expected to be a key factor for growth of the market. For instance, in 2013, researchers at John Hopkins University developed new method for calculating LDL, or low-density lipoprotein. This new method, to calculate LDL (bad cholesterol levels) in the blood, has eliminated inconvenient pre-test fasting. This research also provided evidence that the new method of calculating bad cholesterol levels in the blood is more accurate than the conventional method. Furthermore, key players in the market are focusing on launching new devices for cholesterol testing and this is also expected to drive growth of the global cholesterol testing services market in the near future. For instance, in 2013, ACON Laboratories, Inc. launched its mission cholesterol monitoring system for complete lipid panel testing. This cholesterol monitoring system offers cholesterol testing at relatively low costs.


Key Takeaways of the Cholesterol Testing Services Market:

·         The global cholesterol testing services market is expected to exhibit a CAGR of 7.8% over the forecast period (2017–2025), owing to increasing prevalence of high cholesterol level with rising incidence of obesity, and increasing geriatric population.
·         North America was the dominant region in the global cholesterol testing services market and is expected to retain its dominance over the forecast period (2017–2025). This is owing to increasing prevalence of high cholesterol levels among the population, especially in adults and aged, in the U.S.
·         Key players are focusing on expanding their presence by launching new devices & systems and receiving marketing approvals for their new products in key geographies.
·         Major players operating in the cholesterol testing services market include Quest Diagnostics Incorporated, Spectra Laboratories Inc., Bio-Reference Laboratories Inc., Eurofins Scientific (Luxembourg), Clinical Reference Laboratory, Inc. (CRL), ACM Medical Laboratory, Adicon Clinical Laboratory, Unilabs, SYNLAB International GmbH, and Laboratory Corporation of America Holdings (LabCorp).

About CMI

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Monday, 19 February 2018

Burn Care Market, by Type of Burn, Product Type, End User - Industry Insights, Trends, Outlook and Opportunity Analysis, 2025

Burn wounds are extremely painful, frequently highly traumatic and can lead to permanent scarring, disfigurement or even death. The management of these wounds is based on the injured area, and severity of burns and by the depth includes minor, partial and full-thickness injuries. Burn care market has witnessed various technological advancements and emerged as a standard solution to treat all degrees of burns. Conventional measures of burn care management are being rapidly replaced with advanced products due to the effectiveness of the latter for managing burn injuries, which enables faster healing. The treatment in burn injuries includes intervention therapies and use of products such as traditional and advanced care dressings. The rising number of burn injury cases rising the demand of burn care products globally. In addition to this, the unhealed burns do not only diminish quality of life but also increases the risk of infections and complications. Therefore, burn care is an important part of healing process. Moreover some serious burns may require immediate medical care to prevent further complications and death of patient.

Request to download and view full ToC: https://www.coherentmarketinsights.com/ongoing-insight/toc/1279

Rising fire incidences are increasing the demand for treatment of burn injuries which in turn increasing the usage of burn care products especially in the low and middle income countries.  For instance, in January 2017 , according to the World Health Organization (WHO) data published on African Journal of Emergency Medicines, stated that burn cases accounted around 18 million disability cases and more than 2,50,000 deaths each year of which more than 90% deaths registered from low-and middle-income countries. In addition to this, U.S. fire department responded to around 1.3 million fire incidences in 2016, of which 3,280 civilian deaths and 15,700 civilian injuries reported by National Fire Protection Association (NFPA). 

Burn Care Market Taxonomy:

On the basis of depth of burn, burn care market segmented into:
  • Minor-thickness burn
  • Partial-thickness burn
  • Full- thickness burn
On the basis of product type, burn care market segmented into:
  • Traditional burn care products
  • Advanced dressing
  • Hydrogel dressing
  • Alginate dressing
  • Foam dressing
  • Hydrocolloid dressings
  • Collagen dressings
  • Other dressings
  • Biologics
  • Other burn care products
On the basis of end user, burn care market segmented into:
  • Hospitals
  • Clinics
  • Home care settings
  • Other end users
Introduction of new burn care products will favor the growth of burn care market

New product launches expected to drive the market of burn care products during the forecast period. For instance, in September 2016, ConvaTec, Inc. launched Foam Lite ConvaTec dressing after receiving the CE mark approval for management of low to non-exuding wounds such as skin tears, skin abrasions and partial thickness burns in France, Germany, the U.K., Canada, Australia and New Zealand.

Browse Research Report At: https://www.coherentmarketinsights.com/ongoing-insight/burn-care-market-1279

For instance, in July 2016, a combined team of researchers from the Boston University and Beth Israel Deaconess Medical center developed new type of hydrogel bandage for the burn patients. This new hydrogel bandage allow the easy removal at the time of dressing change, by applying an aqueous solution of cysteine methyl ester. The hydrogel bandage seals the burn wounds to prevent entry of bacteria and proven to be easily removable. Moreover the advancement in the burn care products helps to fuel the demand of burn care market.

Some of the key players in the burn care market include DeRoyal Industries, Inc., Smith & Nephew plc, Devon Medical Products, Inc., PAUL HARTMANN AG, ACell, Inc., ConvaTec Inc., Coloplast A/S, Molnlycke Health Care AB, Medela AG, Acelity L.P. Inc., Derma Sciences Inc. and Medtronic plc.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Monday, 22 January 2018

Diabetes Injection Pens Market, by Product Type, Geography - Global Industry Insights, Trends, Outlook, 2025

Diabetes insulin pens are advanced forms of prefilled insulin syringes and pen needles that are used to inject insulin in the body of patients suffering from type-1 diabetes. These pens usually consist of an insulin cartridge that acts as an insulin reservoir and a dial that is used to measure the exact volume of insulin that is intended to be delivered to the patient. These cartridges and pens are available in different shapes and sizes and are also available in disposable and non-disposable types. Most of the diabetes pens are incorporated with insulin pen needles that are replaceable, thin, and extremely short to reduce the pain caused during injection. Several universal pen needles are also present in the market that fits to almost all the brands of insulin pens. These pens are handy, easy to carry around, and can be used in home settings to provide accuracy in dose delivery. This in turn, is increasing the demand for diabetes insulin pens.

Request to download and view full ToC: https://www.coherentmarketinsights.com/ongoing-insight/toc/1156

Rising incidence of diabetes is expected to propel the demand for insulin injection pens

Rising incidence diabetes is one of the major factors responsible for growth of the global diabetes injection pens market. According to the American Diabetes Association, around 30.3 million of people in the U.S. suffered from diabetes, accounting for up to 9.4% of the total population in 2016. Moreover, according to the BMJ Open Diabetes Research & Care, around 387 million people in the world suffer from diabetes, out of which around 5-10% suffer from type-1 diabetes. Various other factors driving growth of the market include risk of needle-stick injuries and bacterial infection caused by regular use of syringes to inject insulin and the advancements technology related to diabetes pens, leading to development of painless devices for daily insulin injections. However, the availability of insulin patches and other substitutes for insulin delivery are expected to hamper the growth of the market.

Market Taxonomy:

On the basis of product type, the global diabetes injection pen market is segmented into:
  • Insulin Pens
  • Pen Needles
On the basis of usage, the global diabetes injection pens market is segmented into:
  • Reusable
  • Disposable
On the basis of distribution channel, the global diabetes injection pens market is segmented into:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Medical Stores
  • Diabetes Clinics
North America to hold a dominant position in the global diabetes injection pens market, owing to advancements in technology development in the in diabetes pens

On the basis of region, the global diabetes injection pens market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds the dominant position in the global diabetes injection pens market, owing to increasing prevalence of type-1 diabetes as well as development of advanced injection pens by manufacturers in the region. For instance, according to the Centers of Disease Control and Prevention (CDC), around 5% of the people suffering from diabetes are diagnosed with type-1 diabetes and are unable to produce insulin naturally. This increases the demand for external insulin administration. Moreover, according to the Juvenile Diabetes Research Foundation, the healthcare burden due to type-1 diabetes in the U.S. accounted for up to US$ 14 billion in 2016. Asia Pacific is expected to witness fastest growth in the market, owing to rising awareness among the patients as well as evolving healthcare infrastructure.

Key players are focused on development of novel products to sustain their position in the highly consolidated market

Key players operating in the global diabetes injection pens market include Novo Nordisk A/S, AstraZeneca Plc, Biocon Ltd, Eli Lilly and Company, Becton, Dickinson and Company, and Jiangsu Delfu Co. Major players are consistently focused towards innovation and development in the existing technology to maintain their significance and establish their presence in the global diabetes injection pens market. For instance, Novo Nordisk in 2014 introduced a new insulin injection pen device NovoPen Echo that was the first-ever injection pen to deliver half a unit of insulin, with a memory function that records last dose and the time passed since the last injection.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.